Metastatic Uveal Melanoma - Pipeline Review, H2 2016

  • ID: 4030255
  • Report
  • 56 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Celldex Therapeutics Inc
  • Eli Lilly and Company
  • Novartis AG
  • MORE
Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Celldex Therapeutics Inc
  • Eli Lilly and Company
  • Novartis AG
  • MORE
Introduction

Metastatic Uveal Melanoma Overview

Therapeutics Development

Pipeline Products for Metastatic Uveal Melanoma - Overview

Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis

Metastatic Uveal Melanoma - Therapeutics under Development by Companies

Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes

Metastatic Uveal Melanoma - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Metastatic Uveal Melanoma - Products under Development by Companies

Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes

Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development

Bellicum Pharmaceuticals Inc

Celldex Therapeutics Inc

Eli Lilly and Company

Novartis AG

Spectrum Pharmaceuticals Inc

Metastatic Uveal Melanoma - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

alpelisib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPX-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emibetuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glembatumumab vedotin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCN-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LXS-196 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

merestinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sotrastaurin acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vincristine sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Metastatic Uveal Melanoma - Dormant Projects

Metastatic Uveal Melanoma - Discontinued Products

Metastatic Uveal Melanoma - Product Development Milestones

Featured News & Press Releases

Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016

Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Metastatic Uveal Melanoma, H2 2016

Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Metastatic Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016

Metastatic Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016

Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016

Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2016

Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Metastatic Uveal Melanoma - Dormant Projects, H2 2016

Metastatic Uveal Melanoma - Discontinued Products, H2 2016

List of Figures:

Number of Products under Development for Metastatic Uveal Melanoma, H2 2016

Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bellicum Pharmaceuticals Inc
  • Celldex Therapeutics Inc
  • Eli Lilly and Company
  • Novartis AG
  • Spectrum Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll